TICKERNERD
Menu
AMLXAMLXHealthcare · Drug Manufacturers - Specialty & Generic

AMLX Stock Forecast: Amylyx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 16 Oct 2026
$26
−4.74% on the day

The 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. hold a median 12-month price target of $42 — +59.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 15 Oct 2026 — in the upper half.

Market cap
$3.5B
Ticker Nerd rank
55 / 100
Median analyst target
$42
Analysts covering
12
Revenue$0.0
Operating income−$45.7M
Net income−$43.4M
Free cash flow−$31.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.4%
1M
−19.3%
YTD
+118.0%
1Y
+73.6%
From 52W high
−33.6%
From 52W low
+131.5%
$11
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMLX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amylyx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Oct 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Growth
88
Value
76
Volatility
53
Accruals
48
Issuance
40
Quality
36
Revisions
33
Size
28

Momentum (93): The shares have been drifting up relative to others.

Revisions (33): Analysts have, on balance, been cutting their forecasts.

Size (28): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26AMLXHigh $57Median $42Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $20Median $42High $57

The green dot is the last close — the median target sits +59.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
27 Aug 2026GuggenheimMaintainsBuy$55 → $57
19 Aug 2026BairdMaintainsOutperform—
19 Aug 2026BairdMaintainsOutperform$28 → $52
19 Aug 2026GuggenheimMaintainsBuy—
19 Aug 2026GuggenheimMaintainsBuy$40 → $55
19 Aug 2026MizuhoMaintainsOutperform$30 → $42
19 Aug 2026MizuhoMaintainsOutperform—
18 Aug 2026HC Wainwright & Co.MaintainsBuy$34 → $55
18 Aug 2026HC Wainwright & Co.MaintainsBuy—
17 Aug 2026MizuhoMaintainsOutperform—
17 Aug 2026MizuhoMaintainsOutperform$24 → $30
3 Aug 2026CitigroupMaintainsBuy—
3 Aug 2026CitigroupMaintainsBuy$20 → $26
20 July 2026MizuhoMaintainsOutperform—
20 July 2026MizuhoMaintainsOutperform$21 → $24
25 June 2026GuggenheimMaintainsBuy$30 → $40
25 June 2026GuggenheimMaintainsBuy—
28 Apr 2026MizuhoMaintainsOutperform—
25 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMLX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AMLX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 16 Oct 2026, Amylyx Pharmaceuticals, Inc. returned +73.6% against +16.8% for the S&P 500, dividends included.

AMLX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26AMLXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

Amylyx Pharmaceuticals, Inc. (AMLX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
12.5×

Cheaper than 7% of US stocks

EV / EBITDA
−17.5×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−74.7%

Higher than 17% of US stocks

Return on assets
−44.1%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Amylyx Pharmaceuticals, Inc. (AMLX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amylyx Pharmaceuticals, Inc. has a market value of $3.5B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$152.1M.

  • Diluted earnings per share, trailing twelve months: $−1.43.

  • Free cash flow in the twelve months to 30 June 2026: −$126.7M.

  • Shares outstanding: 111.4M.

  • Trailing P/E: 2.5×; forward P/E: −24.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Amylyx Pharmaceuticals, Inc. employs 136 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Oct 2026

Data provided by Twelve Data

Peers

AMLX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMLXAmylyx Pharmaceuticals, Inc.$3.5B
55
LQDALiquidia Corp.$3.1B
77
INDVIndivior Pharmaceuticals, Inc.$4.0B
97
RGCRegencell Bioscience Holdings Ltd.$4.7B
22
PBHPrestige Consumer Healthcare, Inc.$2.4B
62
SUPNSupernus Pharmaceuticals, Inc.$2.3B
74
PRGOPerrigo Co. Plc$2.3B
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amylyx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMLX news & analysis

11 Stocks Most Likely to See a Short Squeeze Rally

Schaeffers Research · 12 Oct 2026neutral

Schaeffers Research published a list titled “11 Stocks Most Likely to See a Short Squeeze Rally.” Its excerpt says bond yields, oil prices, and inflation rhetoric have made conditions difficult for investors heading into earnings season.

Why it matters — The provided excerpt does not identify Amylyx Pharmaceuticals among the stocks or give company-specific information, so it offers no direct AMLX context.

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

Business Wire · 6 Oct 2026neutral

Amylyx Pharmaceuticals announced that it will present topline data from its Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia at the ObesityWeek 2026 Annual Meeting.

Why it matters — The presentation will provide AMLX watchers with an update on the clinical trial of avexitide for post-bariatric hypoglycemia.

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

MarketBeat · 3 Oct 2026positive

Amylyx Pharmaceuticals reported that its Phase III trial of avexitide for post-bariatric hypoglycemia met its primary and all secondary endpoints. This positions the company to submit a New Drug Application to the FDA before the end of the year.

Why it matters — A successful late-stage trial and upcoming FDA filing for avexitide represent a significant pipeline milestone and a potential new commercial opportunity for the company.

10 Stocks With Massive Short Squeeze Potential

Schaeffers Research · 1 Oct 2026neutral

Schaeffers Research reports that rising bond yields, higher oil prices, and inflation rhetoric are creating a difficult environment for investors heading into Q4, and examines where short sellers are positioning their money amid these conditions.

Why it matters — Since the article discusses stocks with short squeeze potential, it may highlight Amylyx among names where short sellers are active, which could matter to AMLX watchers monitoring market positioning.

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Business Wire · 23 Sept 2026neutral

Amylyx Pharmaceuticals announced that it will present at the Stifel 2026 Virtual Cardiometabolic Forum. The presentation is scheduled as part of the company's participation in industry events.

Why it matters — The company's participation in the cardiometabolic forum provides an opportunity for Amylyx to showcase its work in this therapeutic area to investors and the broader industry.

FAQ

Frequently asked questions about AMLX stock

What is the AMLX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. have a median 12-month price target of $42, with estimates ranging from $20 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMLX stock a buy right now?

Of the 12 analysts covering Amylyx Pharmaceuticals, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amylyx Pharmaceuticals, Inc. 55 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMLX?

As at 15 Oct 2026, Amylyx Pharmaceuticals, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will AMLX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +59.5% from the last close, and Ticker Nerd's factor model ranks Amylyx Pharmaceuticals, Inc. 55 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMLX stock forecast for 2030?

No analyst covering Amylyx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $57 over the next 12 months.

How has AMLX stock performed over the past year?

Amylyx Pharmaceuticals, Inc. returned +73.6% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amylyx Pharmaceuticals, Inc. do?

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs.

What is the latest news on AMLX?

The most recent item we track (Schaeffers Research, 12 Oct 2026): "11 Stocks Most Likely to See a Short Squeeze Rally". Schaeffers Research published a list titled “11 Stocks Most Likely to See a Short Squeeze Rally.” Its excerpt says bond yields, oil prices, and inflation rhetoric have made conditions difficult for investors heading into earnings season.

Company

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. The company’s current pipeline centers on endocrine and neurodegenerative disorders, with avexitide as its lead investigational program. Avexitide is being studied as a first-in-class GLP-1 receptor antagonist for conditions linked to excessive insulin activity, including post-bariatric hypoglycemia and congenital hyperinsulinism. Amylyx also advances additional investigational therapies across other rare and serious diseases, reflecting a research portfolio built around well-defined biological targets and measurable clinical outcomes. Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals plays a role in the biotechnology market as a developer of targeted treatments for patients facing limited therapeutic options.

CEO Mr. Joshua B. Cohen · 136 employees · United States · https://amylyx.com